Stereotactic Body Radiotherapy for Oligometastatic Lung TumorsPage 398
Y. Norihisa, Y. Nagata, K. Takayama, Y. Matsuo, T. Sakamoto, M. Sakamoto, T. Mizowaki, S. Yano, and M. Hiraoka
This study retrospectively examined the use of stereotactic body radiotherapy (SBRT) for oligometastatic (that is, a small number of metastases limited to an organ) lung tumors. The study group consisted of 34 patients with such tumors in the lung, colorectum, head and neck, kidney, breast, or bone. The overall survival rate, local relapse-free rate, and progression-free rate at 2 years were 84.3%, 90.0%, and 34.8%, respectively. No local progression occurred in patients irradiated with 60 Gy, and the highest incidence of SBRT-related pulmonary toxicities was of the Grade 2 type, at 12%. The clinical efficacy of SBRT was comparable to that of surgical metastasectomy, which makes SBRT an appropriate alternative treatment.
Health-Related Quality of Life 2 Years After Treatment With Radical Prostatectomy, Prostate Brachytherapy, or External Beam Radiotherapy in Patients With Clinically Localized Prostate CancerPage 421
M. Ferrer, J. F. Suárez, F. Guedea, P. Fernández, V. Macías, A. Mariño, A. Hervas, I. Herruzo, M. J. Ortiz, H. Villavicencio, J. Craven-Bratle, O. Garin, F. Aguiló, and the Multicentric Spanish Group of Clinically Localized Prostate Cancer
These authors examined the quality of life associated with the most common treatments for localized prostate cancer (radical prostatectomy, brachytherapy, and external beam radiation therapy). Specific and generic measures of health-related quality of life were administered to patients before the intervention and during 2 years of follow-up. The most notable difference among therapies found 2 years after treatment was that brachytherapy showed the fewest side effects on sexual functioning and bowel and urinary continence, although it caused moderate urinary irritation. This information may be useful for making treatment choices, both for physicians and patients.
A Phase II Trial of Brachytherapy Alone After Lumpectomy for Select Breast Cancer: Tumor Control and Survival Outcomes of RTOG 95-17Page 467
D. W. Arthur, K. Winter, R. R. Kuske, J. Bolton, R. Rabinovitch, J. White, W. F. Hanson, R. M. Wilenzick, and B. McCormick
This is a disease control report from the cooperative group phase I-II trial, RTOG 95-17, which is investigating accelerated partial breast irradiation (APBI) following breast conserving surgery for early-stage breast cancer. Ninety-nine highly selected patients were treated over a 5-day period with multicatheter brachytherapy to a partial breast target. With an overall median follow-up of 7 years, 5-year estimates of in-breast, regional, and contralateral treatment failures were 4%, 3%, and 3%, respectively. These excellent results continue to support the concept of APBI and are comparable to other partial breast treatment experiences with a similar extended follow-up.
Augmentation of Radiation Response by Panitumumab in Models of Upper Aerodigestive Tract CancerPage 534
T. J. Kruser, E. A. Armstrong, A. J. Ghia, S. Huang, D. L. Wheeler, R. Radinsky, D. J. Freeman, and P. M. Harari
Panitumumab, a fully human anti-EGFR monoclonal antibody, has recently been approved by the FDA for the treatment of metastatic colorectal cancer. First, the impact of panitumumab on tumor cell survival, apoptosis, and DNA damage in combination with radiation was examined in vitro. This showed favorable interactions between panitumumab and radiation in models of head and neck (H&N) squamous cell carcinoma and non–small-cell lung cancer (NSCLC). Panitumumab was also shown to augment the tumor xenograft response to fractionated radiation in animal model systems. These data suggest that clinical investigations are warranted that examine the combination of radiation and panitumumab in the treatment of H&N and NSCLC.
FULL TEXT
Page 398